A new CAR T-cell therapy attacks supportive cells in the tumor microenvironment that bear the surface protein, uPAR.

Often diagnosed when surgery is no longer an option, pancreatic cancer is one of the most difficult cancers to treat and has ...

A key question for ESO-T01 and other in vivo candidates will be the durability of their cancer eradication. While the ...

Often diagnosed when surgery is no longer an option, pancreatic cancer is one of the most difficult cancers to treat and has ...

Enabling patients to generate CAR T-cells internally could cut kidney cancer therapy costs, explained Dr. Wayne Marasco of Dana-Farber Cancer Institute. In vivo CAR T-cell therapy could drastically ...

A cell-based immunotherapy designed to treat rare and aggressive types of blood cancer has been granted Breakthrough Therapy ...

Chimeric antigen receptor T-cell therapy—CAR T for short—has been a major advance in treating blood cancers like leukemia and ...

CAR T-cell therapy is being adapted for clear cell renal cell carcinoma, targeting CAIX and CD70 to improve efficacy and safety. Early trials like COBALT-RCC and TRAVERSE show promising disease ...

CAR T-cell therapy shows promise for SCLC, but significant barriers, such as tumor heterogeneity and immunosuppression, must be addressed. Identifying tumor-selective antigens like CDH17, GD2, and ...

Data are beginning to provide a clearer picture of chimeric antigen receptor T-cell therapy’s benefits and risks in lupus, ...

BCMA CAR T approvals (ide-cel 2021; cilta-cel 2022) deliver near-98% response in trials but require specialized centers, creating logistical constraints on access. Across >9 million UC patients, ...

The curious minds at ColdFusion break down CAR-T therapy designed to target and kill cancer cells. Republicans pull off shock result in Virginia special election Contributor: Ukraine's aid against ...